The purpose of this study is to determine whether interleukin-2 given 3 times weekly for 8 weeks in combination with rituximab is effective and safe when compared to rituximab given alone in the treatment of follicular NHL subjects that have never received rituximab as a treatment and are refractory or relapsed after previous chemotherapy.
CD20+ follicular B-cell non-hodgkin's lymphoma with at least 1 site of measurable disease. Previous treatment with 1 to 4 prior chemotherapy regimens ECOG performance status of greater than or equal to 2 Life expectancy of greater than 18 weeks Meet safety lab requirements and organ function tests
Exclusion Criteria:
Prior treatment with rituximab or IL-2 Prior radioimmunotherapy including Zevalin or Bexxar 5 or more prior chemotherapy regimens Clinically significant cardiac disease, lung dysfunction, autoimmune disease, thyroid disease, active infection, unstable psychiatric condition, or HIV infection. History of allogenic bone marrow transplant Female subjects that are pregnant or breast feeding Immunosuppressive therapy including corticosteroids or investigational agents within 4 weeks prior to the planned start of study treatment
